Overview
Description
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Denmark
Financials
Key metrics
Market capitalisation, EUR | 4,083.70 m |
EPS, EUR | -2.32 |
P/B ratio | 3.65 |
P/E ratio | - |
Dividend yield | 0.00% |
Income statement (2024)
Revenue, EUR | 8.41 m |
Net income, EUR | -144.68 m |
Profit margin | -1,720.87% |
What ETF is Zealand Pharma A/S in?
There are 154 ETFs which contain Zealand Pharma A/S. All of these ETFs are listed in the table below. The ETF with the largest weighting of Zealand Pharma A/S is the Xtrackers Nordic Net Zero Pathway Paris Aligned UCITS ETF 1C.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.